Summary.-The relationship between carcinoembryonic antigen (CEA) and A antigenic determinants on the cell surface of colon-tumour cells was studied by the ADCC assay. Antiserum prepared in 2 rabbits to an undecapeptide analogous to the amino terminal of CEA(l -11) was found by us either to participate in (Rabbit 2) or specifically inhibit (Rabbit 1) ADCC. The binding spectra of these two antisera and of antiserum to the whole CEA molecule were similar. All of them react with A and non-A colon-tumour cells as well as red blood cells of Type A (RBC-A) and their activity was completely absorbed on RBC-A but not on B or 0. 0-type, ADCCreactive human sera always react with A-type colon-tumour cells and RBC-A, and some of them with non-A colon-tumour cells also. The degree of inhibition of their reactivity by anti-CEA(l -11) RI varied between sera, from none to almost a complete inhibition, and is not related to whether the serum is of cancer or non-cancer origin. Non-reactive 0-type sera contain anti-A activity demonstrable by haemagglutination and immunofluorescence. However, they cannot participate in ADCC reaction nor inhibit it. The sera, which contain lymphocyte-dependent antibody to A-type colon-tumour cells, lysed RBC-A, without the addition of lymphocytes or complement, in an immunologically specific way. It is concluded that the reactivity seen in our ADCC system is related to a determinant common to A and CEA (and maybe to other normal cross-reacting antigens) which most probably resides in the amino terminal part of these molecules. This determinant elicits the production of lymphocyte-dependent antibodies in about 50o/ of people with blood group 0. Thus, the amino terminal part of CEA is not a tumour-specific part of the CEA molecule. No specific anti-tumour activity was found in patients' serum by this method, and claims for its demonstration by other methods may well be related to the non-specific activity observed here.
IN the preceding article (Shoham & Cohen, 1979) , the antibody-dependent cellular cytotoxicity (ADCC) reaction against human colon-tumour cells was used to test cellular and humoral activity in cancer patients and healthy controls. Definite humoral activity was found in 21%0 of the sera tested. However, this reactivity was not related to disease state but to blood-group 0, and was apparently anti-A activity per se. On the other hand, "A-like activity" was demonstrated in purified preparations of CEA (Gold & Gold, 1973) and there is still controversy regarding its significance. Some people regard it as impurity due to separable A molecules (Lo Gerfo et al., 1972) , some relate it to the blood group of the patient and found respectively A, B or Lespecific determinants attached to the CEA molecule (Holburn et al., 1974) and some claim that it is an innate characteristic of the CEA molecule, unrelated to the blood group of the patient (Gold & Gold, Correspondence to: Dr Jacob Shoham, The Genetic Institute, Sheba AMedical Center, Tel-Hashomer, Israel. 1973). The expressioni of this and other determinants when the CEA molecule is part of the cell surface is even less understood.
The present experiments were undertaken in order to study the relationship between A and CEA on the cell surface, and their relative contribution to the ADCC reaction. In addition, the possibility of demonistrating a moire specific tumour-directed activity by using inhibitory antisera was also evaluated.
MATERIALS AND METHODS
Cell lines wAere the same as in the previous study (Shoham & Cohen, 1979) but in addition, 2 other colon-tumour cell lines were used: HCT-8 and 4788, kindly given to us by Dr M Goldrosen from Roswell Park Memorial Inistitute. Buffalo, N.Y., U.S. Cell cultures Aere done as in the previous study.
Serla. Goat anti-CEA serum wA-as produced as in Shoham & Cohen (1979) . Rabbit anti-CEA(1-11) was antiserum prepared by Dr Arnon and her group (Arnon et al., 1976) against a synthetic peptide corresponding to the I-amino-acid residues of the amino terminal portion in the sequence of CEA conjugated to BSA, and *was kindly given to us bv them. Anti-A and anti-B blood grouping serum, prepared from the blood of donors hyperimmunized wA-ith blood-group-specific substances, Mwas purchased from Hyland (Div. Travenol Labs, CA). ADCC reactive and non-reactive human sera wAere selected from our previous study. Surface immnunofuorescence.-Cells were harvested and incubated with the tested serum for 30 min at room temperature then washed and incubated with fluorescein-conjugated antiserum to the tested serum.
RESULTS

Determination of blood group of the colontumour cell lines
This was done by 2 methods: mixed haemadsorption and imnmunofluorescence using commercial typing serum. It was found that ACC-20 and HT-29 had bloodgroup A antigen, and this was confirmed from the known blood group of the patients. Lines HCT-8 and 4788 were found to be non-A (0).
Absorption of anti-CEA on RBC Anti-CEA absorbed on RBC 0 or B retained about the same activity as nonabsorbed serum. However, absorption on RBC-A eliminated ADCC activity almost completely. Similar results were obtained with ADCC-reactive 0-type human serum (Table I) . Thus, anti-CEA prepared against the whole CEA molecule is strongly crossreacting with antigen A on RB(1. There- fore, for further experiments we introduced antisera prepared against a synthetic peptide corresponding to the 11 amino-acid residues of the amino terminal portion of the sequence of CEA :anti-CEA (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . This is obviously a different determinant from the known A determinant.
ADCC with A-type colon-tumour cells Antisera prepared in 2 rabbits (RI and R2) against CEA(-1l1) conjugated to BSA, both found to be active in the bacteriophage-inactivation assay for CEA (Arnon et al., 1976) , were compared for the ADCC activity on A-type colon-tumour cells. Surprisingly, these 2 antisera differed completely in their ADCC activity. RI antiserum was completely devoid of activity, whereas R2 antiserum was more potent than anti-CEA (Table II) . However, when cells were incubated first with anti-CEA( 1-11) RI and then with anti-CEA(I-11) R2, the ADCC activity of the R2 antiserum was almost completely inhibited. Thus, Rabbit 1 produced antibodies that cannot participate in the ADCC reaction, but were avidly bound to CEA either in the phage assay or on the cell surface. Similar inhibitory activity of anti-CEA(1-11) RI was also exerted on anti-CEA activity. On the other hand, the activity of anti-A, as well as that of reactive 0-type human serum, was only partially inhibited. Moreover, if RI antiserum was absorbed on RBC-A it completely lost its inhibitory activity to all the sera tested. A non-reactive 0-type human serum (S-113) was completely without inhibitory activity, although it contains strongly agglutinating anti-A and anti-B (Table II) .
We tested the possibility of using the inhibitory activity of anti-CEA(I -11) RI for differentiating between cancer and non-cancer sera. The results (Table III) indicate that the degree of inhibition varies considerably from 0 to 90%. However, the degree of inhibition does not correlate with the disease state of the patient.
ADCC with non-A colon-tumour cells ti-A 8-0 7-5 ti-B 6-4 5-9 ti-CEA(1-11) R2 8-5 10-2 z 04(-)t 7-1 6-3 59 (+) 6-8 7-7 4 3(+) 6-1 5-5 3 4 (-) 6-5 6-1 HT-29 cells may be either wholly nonreactive (S-204) or reactive to RBC-B only (S-84). On the other hand HT-29-reactive sera may be reactive either with RBC-A and B (S-259) or RBC-A only (S-83).
Anti-CEA(1-11) RI was used for inhibition experiments on RBC-A, similar to that done on (Table VII) . R2 antiserum was strongly inhibited whereas anti-CEA and S-141 were only partially and anti-A activity was quite unaffected. Thus, the inhibition of serum activity was much less effective on RBC-A than on HT-29 cells (compare Tables VII and II) . Once more, anti-CEA(I-11) RI absorbed on RBC-A was completely devoid of inhibitory activity.
Binding to cell-surface immunoftuorescence study
The antisera used in this study were tested for their ability to bind to the cell surface. (Fig. A-D) . It has to be remembered that R1 is the inhibitory and R2 is the reactive serum in ADCC. Anti-A was reactive with HT-29 and ACC-20 and, of course, RBC-A, but not with O-type human sera were also tested in this way. Most of the sera gave positive surface fluorescence whether or not they contained lymphocyte dependent activity (LDA). However, with some of the sera no fluorescence appeared, and this happened with either LDA positive or negative sera. The fluorescent pattern was that of a continuous rim or patches but occasionally more regional distribution was noticed (Fig. E-F) .
DISCUSSION
In order to evaluate the relationship between the antigens CEA and A on the cell surface, we introduced antisera with apparent selectivity to one of them, anti-CEA(1-I 1) and anti-A respectively, and cell types which bear only one of the antigens (non-A colon-tumour cells vs RBC-A). Anti-CEA(1-11) from Rabbit 1 and Rabbit 2 (RI and R2) have similar binding capacity. However, R I inhibits and R2 participates in the ADCC reaction. Inhibition of ADCC was demonstrated in other systems, but it is by a mechanism which seems to be different from the one described here. Soluble immune complexes (MacLennan, 1972) , IgG aggregates (Greenberg et at., 1973) or antibodies attached to cell-surface antigens of the effector or "third party" cells (Halloran et al., 1974) (Fuks et al., 1975) . XVe must asstume a common antigenic determinant to CEA and A which resides in another part of the molecule, and as CEA (I-1l) corresponds to the N-terminal part of the CEA molecule, we tentatively ascribe the common activity to this part of the molecule. However, as the carrier molecule of the ABO antigens is most probably common to all of them, we further assume that although the N terminal may be common to other antigens (including B and 0 (H)) it is exposed conformationally only in A and CEA. Alternatively, certain small differences in the primary sequence of a peptide determinant may change antigenicity in similar molecules like those of the ABO system. The heterogeneity found in the N-terminal of CEA (Wang et al., 1976 ) may be cited in support of such possibility. This molecular segment may also participate in the cross-reactivity of CEA with normal glycoprotein antigens (Von Kliest, 1973) on the cell surface and it. will be worth while to look for its presence in them. In any case, the CEA( Il l) determinant is not tumour-specific at all. However, the antiserum prepared against it did help to solve the controversy over the source of the "A-like site", indicating it to be an innate and common characteristic of both the CEA and A molecules. This may also explain the confusing observation of "CEA-like activity" on erythrocyte membranes (Nery et al., 1973; Taylor & Freed, 1976) .
The activity of the 0-type ADCCreactive human sera is less clearly delineated. They always react with A-type colon-tumour cells and RBC-A, and some of them with non-A colon-tumour cells also. The degree of inhibition of their reactivity by anti-CEA( 1-11) RI varies from one serum to the other, from none to almost complete inhibition, and is not related to the serum being of cancer or non-cancer origin. Sometimes they also contain anti-B activity. Hence, the reactive sera contain LDA which are directed, at least partially, to the common determinant of CEA and A, as judged from the experiments on the non-A tumour cells and the inhibition by anti-CEA(1-II) RI. We have no explanation of the fact that only 50%0 of 0-type people produce LDA active in this system, and it will be of interest to determine whether this activity is genetically controlled. This may be related either to different genetic control of immune responsiveness or to individual differences in the antigenic determinant involved. In this connection, the difference between the antisera produced in the 2 rabbits to CEA(1-11) (Ri = inhibitory, R2 = reactive in ADCC) is also of some interest, and seems to be related rather to difference in immune responsiveness.
Non-reactive 0-type sera do contain anti-A activity, which is demonstrated by haemagglutination and immunofluorescence. However, they cannot participate in ADCC reaction nor inhibit it. The absence of inhibitory activity may be related either to the fact that they bind only to the N-acetylgalactosamine determinant and do not block the other site, or because they bind to the same site as the LDA, but less avidly and are easily replaced.
In conclusion, the reactivity demonstrated in our system was shown to be related to a determinant common to A and CEA which is not N-acetyl-D-galactosamine. No specific anti-CEA activity was found, and we wonder whether such activity exists at all. The only evidence that is cited for anti-CEA activity in human sera is the work of Gold & Gold (1973) and Gold et al. (1972) and the demonstration of CEA in immune complex nephropathy in a patient with colon tumour (Costanza et al., 1973) . However, both may be related to the phenomenon described here.
One unexpected observation deserves comment. The serum which contains LDA active to A-type colon-tumour cells exhibited a peculiar lytic effect on RBC-A; the lysis took place without the addition of lymphocytes or complement, whereas the lysis of the antibody-coated tumour cells was absolutely dependent on the addition of lymphocytes. This reaction is immunologically specific and the possibilities of non-specific toxic effect of the serum or residues of either complement or mononuclear cells in the serum or RBC preparations, respectively, were reasonably excluded. This reaction is now being further explored by purified immunoglobulin fractions of these sera, before any further conclusions from this observation are drawn.
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